GU Debates 2019: Practice-changing developments in urothelial cancer (2/2)

Bookmark and Share
Published: 9 Apr 2019
Views: 1698

Dr Eleni Efstathiou chairs a discussion with Prof Thomas Steuber, Prof Peter Goebell and Prof Joaquim Bellmunt on the recent data presented at the 2019 GU Debates in Budapest, with a specific focus on patients with prostate and urothelial cancers.

In this video, the group acknowledge the sudden shift in bladder cancer research - which has resulted from genomic advances; including the use of The Cancer Genome Atlas Program (TCGA).

A more personalised treatment approach is anticipated in first-line metastatic urothelial carcinoma, along with checkpoint inhibition and targeted therapies; with potential applicability to the second-line setting.

The group also discuss novel data showing prolonged survival in the metastatic setting with immunotherapeutic agents; along with five phase III trials - in which the results are expected to be practice-changing.

They also conclude the discussion by highlighting the importance of patient communication in the clinic.

Watch part 1 of this video which covers the changing treatment paradigms for hormone-naïve and castration-resistant prostate cancer here.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).